KEPPRA 250 MG 30 TAB

126.00 EGP

Each film-coated tablet contains : levetriracetam 250 mg.

KEPPRA 250 MG 30 TAB; levetiracetam, anticonvulsants .

ACTIVE-INGREDIENT OF KEPPRA 250 MG 30 TAB

Each film-coated tablet contains : levetriracetam 250 mg.

INDICATION OF KEPPRA 250 MG 30 TAB

Levetiracetam is indicated as monotherapy in the treatment of : partial onset seizures with or without secondary generalization in adults and adolescents from 16 years of age with newly diagnosed epilepsy. Levetiracetam is indicated as adjunctive therapy in the treatment of : partial onset seizures with or without secondary generalization in adults , adolescents children and infants from 1 month of age with epilepsy, myoclonic seizures in adults an adolescents from 12 years of age with juvenile myoclonic epilepsy, primary generalised tonic – colonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

DOSAGE OF KEPPRA 250 MG 30 TAB

Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet

Ask your pharmacist or doctor for help if you do not understand the instructions on the box .

The recommended dose is : –

The film coated tablets must be taken orally, swallowed with a sufficient quantity of liquid and may be taken with or without food. The daily dose is administered in two equally divided doses. Route of administration : keppra 250 , 500 ,1000 mg, film – coated tablets for oral use. Adults : monotherapy : adults and adolescents from 16 years of age : the recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily. Add- on therapy . Adults ( > 18 years) and adolescents ( 12 to 17 years) weighing 50 kg or more. The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks. Children : the physician should prescribe the most app pharmaceutical form, presentation and strength according to age, weight and dose. The tablet formulation is not adapted for use in infants and children under the age of 6 years . Levetiracetam and oral solution is the preferred formulation for use in this population. In addition, the available dose strength of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for children , for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases levetiracetam oral solution should be used. Monotherapy : the safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established. There are no data available. Add – on therapy for children aged 4 to 11 years and adolescents ( 12 to 17 years) weighting less than 50 kg. Keppra oral solution is the preferred formulation for use in infants and children under the age of 6 years. The initial therapeutic dose is 10 mg / kg twice daily. Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg / kg twice daily. Dose changes should not exceed increases or decreases up to 30 mg / kg twice daily. Dose changes should not exceed increases or decreases of 10 mg / kg twice daily every two weeks. The lowest effective dose should be used. Dose in children 50 kg or greater is the same as in adults. Dose recommendations for infants from 6 months of age, children and adolescents : weight : starting dose 10 mg/kg twice daily : maximum dose 30 mg / kg twice daily. Weight 6 kg ( 1) : 60 mg ( 0.6 ml ) twice daily : 180 mg ( 1.8 ml) twice daily. 10 kg : 100 mg (1 ml ) twice daily : 300 mg (3 ml ) twice daily . 15 kg : 150 mg (1.5 ml) twice daily : 450 mg ( 4.5 ml ) twice daily . 20 kg : 200 mg ( 2 ml ) twice daily : 600 mg ( 6 ml ) twice daily . 25 kg : 250 mg twice daily : 750 mg twice daily . from 50 kg : 500 mg twice daily : 1.500 mg twice daily . children 25 kg or less should preferably start the treatmen with keppra 100 mg / ml oral solusion . dose in children and adolescents 50 kg or more is the same as in adults . add-on therapy for infants aged from 1 month to less than 6 month the oral solusion is the formulation to use in infants . elderly : adjustment of thje dose is recommended in elderly patients with compromised renal function . renal impairment : the daily dose must be individualised according to renal function . for adult patients , refer to the frollowing table and adjust the dose as indicated . to use this dosing table , an estimate of the patient’s creatinine clearance ( CLcr ) in ml/min is needed . the CLcr in ml/min may be estimated from serum creatinine ( mg/dl ) determination , for adults and adolescents weighting 50 kg or more , using the following formula : clcr ( ml/min ) = [ 140 – age [years ] × weight ( kg) / 72 × serum creatinine( mg/dl) ( × 0.85 for women ) . then clcr is adjasted for body surface area ( BSA) as follows : clcr ( ml/min / 1.73 m2 ) = clcr(ml/min ) / BSA subject m2) × 1.73 . dosing adustment for adult and adolescent patients weighing more than 50 kg with impaired renal function .

OVER-DOSAGE OF KEPPRA 250 MG 30 TAB

symptoms and signs : somnolence , agitation , aggression , depressed level of consciousness , respiratory depression and coma were observed with levetiracetam overdoses . Treatment : after an acute overdose , the stomach may be emptied by gastric lavage ior by induction of emesis . there is no specific antidote for levetiracetam . treatment of an overdose will be symptomatic and may include haemodialysis . the dialyser extraction effeciency is 60 % for levetiracetam and 74 % for the primary metabolite . further management should be as clinically indicated or as recommended by the national poisons centre , where available .

CONTRA-INDICATION OF KEPPRA 250 MG 30 TAB

levetiracetam is contraindicated in : hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients .

STORAGE OF KEPPRA 250 MG 30 TAB

Store at a temperature not exceeding 30 °C.
PACK OF KEPPRA 250 MG 30 TAB
3 or 6 ( AL/PVC) blisters each of 10 tablets placed into cardboard boxes and inner leaflet .
KEPPRA 250 MG 30 TAB MANUFACTURED BY
USB PHARMA SA, CHEMIN DU FORIEST , 1420 BRAINE

https://www.drugs.com/search.php?searchterm=levetiracetam&a=1

https://www.gardeniapharmacy.com/category/medicine-2/

Form

Gender

How to use

Reviews

There are no reviews yet.

Show reviews in all languages (1)

Be the first to review “KEPPRA 250 MG 30 TAB”

Your email address will not be published. Required fields are marked *

Shopping Cart
Don`t copy text!
Scroll to Top
Open chat